LifeArc published an article by Senior Analyst Joe Baxter reflecting on the lessons from the Paediatric Therapeutic Development Workshop series.
Published
Signal category
Research & Knowledge
Quote
“In our latest article, Senior Analyst Joe Baxter reflects on the lessons from the workshop series.”
— LifeArc team
Company
LifeArc
Transforming science into life-changing treatments for people living with rare diseases and drug-resistant infections.
- Industry
- Non-profit Organizations
- Location
- London, GB
- Company size
- 434 employees
LifeArc® is a self-funded medical research organisation with one clear purpose – transforming the lives of people living with rare diseases and drug-resistant infections. We aim to deliver this by conducting and funding pioneering research, and working with partners to accelerate the translation of scientific breakthroughs into new tests and treatments. Our vision is a world where people living with rare diseases and drug-resistant infections can access effective, life-changing treatments faster. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines – Keytruda®( cancer), Actemra® (rheumatoid arthritis), Tysabri® (multiple sclerosis) and Entyvio® (Crohn’s disease). Find out more about our work at www.lifearc.org or follow us on LinkedIn, X (@lifearc1) or Bluesky (@lifearc.bsky.social)